This series was developed to foster entrepreneurial thinking in our research programs, clinical environments, educational endeavors, and service components.

Our Seminar Series speaker will be Donavon McConn, PhD. Dr. McConn is a seasoned biotechnology professional currently the Sr. VP of Development at Vasque Bio, a stealth Biotech company aimed at rare vascular indications. Previously, Donavon was the CEO of Ostentus Therapeutics, a natural products oncology company and Head of Development at XinThera where he drove the scientific programs that led to its acquisition by Gilead in 2023.

In his ~28 years of industry experience, Donavon has submitted >30 INDs and taken numerous assets into clinical development, including 3 marketed products (TivicayTM, TykerbTM and YupelriTM). Donavon was also a Partner with Takeda Ventures and the former Chief Operating Officer of Solent and Amergin Therapeutics. He has also consulted for numerous small and large companies throughout his career. Donavon’s career (GSK, Theravance, Takeda, XinThera, etc.) spans the full drug discovery paradigm from target identification and validation up to and including NDA and MAA submissions across multiple modalities and therapeutic areas.

Donavon earned his BS in Physiology and Biochemistry at UC Davis, and subsequent PhD in Pharmaceutics at the University of Washington.

View on site | Email this event

Meet our renowned facultyConnect with current PharmD studentsLearn about PharmD career opportunitiesEnjoy a provided dinnerTake home a CU Pharmacy swag bagBefore the Open House, take an optional tour of the CU Anschutz campus.

View on site | Email this event